On November 5, 2019 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, reported management’s participation in the following industry and investor conferences in November (Press release, Immunic, NOV 5, 2019, View Source [SID1234550379]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

November 11-13: 25th Annual BIO-Europe International Partnering Conference: Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the 25th Annual BIO-Europe International Partnering Conference in Hamburg, Germany, on Tuesday, November 12, at 9:30 am CET.

November 19-20: Stifel 2019 Healthcare Conference: Dr. Vitt will present a company overview at the Stifel 2019 Healthcare Conference in New York on Tuesday, November 19, at 8:35 am ET.

November 20-21: Jefferies 2019 London Healthcare Conference: Sanjay Patel, CFA, Chief Financial Officer of Immunic, will host 1×1 meetings at the Jefferies 2019 Healthcare Conference in London on Wednesday, November 20 and Thursday, November 21.